Aptevo Therapeutics KUV 2024

Aptevo Therapeutics làm gì?

Aptevo Therapeutics Inc is a biopharmaceutical company focused on researching and developing therapeutic products to treat life-threatening diseases. The company was founded in 2016 as Aptevo Therapeutics Inc from the spin-off of Emergent BioSolutions and is headquartered in Seattle, Washington. Aptevo Therapeutics' business model is based on developing innovative therapy options for medical areas such as oncology, hematology, autoimmune diseases, and infectious diseases. It focuses on the discovery of new antibodies and proteins, as well as the development of novel immunotherapies. Aptevo operates in three main divisions: hemophilia, oncology, and immunosuppression. In the hemophilia division, Aptevo is developing a novel therapeutic protein called IXINITY, which is used to treat bleeding in hemophilia patients. IXINITY is marketed in the United States and Canada and is the only high-purity factor IX concentrate manufactured without human or animal plasma. Aptevo's oncology division is developing a range of immune-oncology products that aim to stimulate the body's immune system to fight cancer. The leading product in this division is the bispecific antibody product APVO436, which targets the treatment of acute myeloid leukemia. APVO436 is currently in Phase I studies. In the immunosuppression division, Aptevo is developing an immune-modulating protein called MOR209, which aims to suppress excessive immune response in various autoimmune diseases. Aptevo has established a partnership with Bavarian Nordic for the development of MOR209 in certain indications. Additionally, Aptevo also offers research and development services. It has two business units: Aptevo BioTherapeutics LLC and Hemophilia BioPharmaceuticals Inc. These two business units offer customized services such as bioprocess design, protein purification and analysis, and cell line development. Aptevo collaborates closely with leading academic research institutions and biopharmaceutical companies to expand its pipeline and develop new products. Aptevo's key partners include the National Institutes of Health, the National Cancer Institute, and the Leukemia and Lymphoma Society. Moreover, Aptevo has established strategic partnerships with companies such as Pfizer and Allergan for the development and commercialization of products in specific therapeutic areas. Overall, Aptevo Therapeutics offers a wide range of products and services in the field of biopharmaceuticals. With its innovative research and development strategy, Aptevo has the potential to achieve a leading position in the biopharmaceutical market and make significant contributions to medicine. Aptevo Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.